{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"DAREON-9","nct_id":"NCT05990738","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dareon-9-nct05990738. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Part A: BI 764532 low dose + topotecan/single agent chemotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Part A: BI 764532 medium dose + topotecan/single agent chemotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Part A: BI 764532 high dose + topotecan/single agent chemotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Part B: BI 764532 + topotecan","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"conditions":["Small Cell Lung Carcinoma (SCLC)"],"enrollment":{"count":69,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"BI 764532","otherNames":["Obrixtamig"],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"Single agent chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-15","lead_sponsor":"Boehringer Ingelheim","official_title":"DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With a Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-based Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-03-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A: Occurrence of dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period","timeFrame":"up to 9 weeks"},{"measure":"Part B: Occurrence of DLTs during the on-treatment period","timeFrame":"up to 36 months"},{"measure":"Part B: Occurrence of AEs during the on-treatment period","timeFrame":"up to 36 months"}],"references":[],"start_date":{"date":"2024-02-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","url":"https://clinicaltrials.gov/study/NCT05990738"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dareon-9-nct05990738"}